Feed or feed supplements for farm animals
A modular feed supplement with a core and structured coating system using exfoliated mineral fillers addresses the issue of inefficient digestion in monogastric animals, providing controlled release and enhanced metabolic efficiency.
Patent Information
- Application Number
- JP2022526472
- Authority / Receiving Office
- JP · JP
- Patent Type
- Patents
- Current Assignee / Owner
- Priority Date
- 2019-11-07
- Filing Date
- 2020-11-09
- Publication Date
- 2024-11-08
- Estimated Expiration
- 2040-11-09
AI Technical Summary
Existing feed supplements for monogastric animals fail to provide controlled release of active substances, leading to inefficient digestion and metabolism due to unsuitable coating systems that dissolve in the animal's digestive system, often requiring enzymes and microflora action, and do not adapt to different animal genera and stages of maturation.
A modularly stacked feed or feed supplement comprising a core with a water-soluble aqueous phase and a lipophilic lipid phase, coated with a structured biocompatible material, utilizing exfoliated mineral fillers like smectite to control release and enhance digestion efficiency.
The solution allows for controlled release of nutrients in precise digestive zones, enhancing metabolism and growth by stabilizing the particles, limiting leakage, and ensuring efficient absorption in monogastric animals.
Smart Images

Figure 0007579591000001 
Figure 0007579591000002 
Figure 0007579591000003
Abstract
Description
[Technical field]
[0001] The present invention relates to a feed or feed supplement for monogastric animals, in particular fish, and in particular to a feed or feed supplement that allows for a controlled release of an active substance that it contains. [Background technology]
[0002] The use of biologically active substances to supplement the diet of farmed animals in order to improve their hygiene and promote their growth is well known.
[0003] Such bioactive substances can be any form of feed supplements, including proteins, lipids, carbohydrates, but also vitamins, and prebiotics, probiotics, amino acids, antioxidants or other molecules of direct or indirect nutritional or therapeutic purpose (i.e. essential oils).
[0004] The diversity of conditions under which feed is ingested and digested requires adapted responses for different genera of animals and different stages of maturity.
[0005] For example, JP 10-327770 describes microcapsules containing a water-soluble active substance dispersed in a lipid phase containing a fat-soluble active substance, the whole being coated with a biodegradable polymer dispersed during production in a mixture of oil and organic solvent. The size of the microcapsules is 5-20 μm, making them suitable for rotifer feed, which is fed to farmed juvenile fish. Examples of biodegradable coating polymers include polysaccharides, polypeptides, aliphatic polyesters, and gelatin. Polysaccharides are preferred. The method of producing the coating system described in that document requires dissolving the coating biopolymer in an organic solvent, which is not recommended for products intended to enter the food chain. Furthermore, the coating system can only be dissolved in the animal's digestive system by chain cleavage. This requires appropriate kinetics and enzymes, which are often obtained by the action of the microflora at the end of the intestine. For example, cellulose cannot be digested by fish because it is not capable of carrying out these chain cleavage. As a result, digestion can be slow and delayed due to the low digestibility of the fibers used.
[0006] There is an interest in feeds or feed supplements, their structure and methods of manufacture, which allow the proposed treatments to be adapted to different genera of animals and different stages of maturity.
[0007] Furthermore, there is a need for feeds and feed supplements that allow a rapid but continuous release of active substances or nutrients in precise and specific zones of the digestive system of the target animal, in particular for better metabolism of these nutrients. Summary of the Invention
[0008] The subject of the present invention are the following products: A feed or feed supplement in the form of a modularly stacked object O allowing controlled release of nutritionally and / or physiologically active substances for monogastric animals, comprising a core 12 and a coating 14 on the core 12, characterized in that the core 12 comprises an aqueous phase A comprising a water-soluble active substance, and a lipid phase 18 comprising a fat-soluble active ingredient, the lipid phase 18 comprising a mineral filler. 1. A feed or feed supplement allowing controlled release of nutritionally and / or physiologically active substances for monogastric animals, comprising a core 12 and a coating 14 on the core 12, the core comprising an aqueous phase A containing a water-soluble active substance, and a lipid 18 containing a fat-soluble active ingredient, the aqueous phase A consisting of gel particles 16, the particles 16 being dispersed in the lipid phase 18, and the lipid phase 18 comprising an exfoliated mineral filler selected from the group of phyllosilicates. The feed or feed supplement is therefore in the form of a modularly stacked object O. 2. A feed or feed supplement as described in product 1, wherein the phyllosilicate is a smectite. 3. A feed or feed supplement according to any one of the preceding products, wherein the dispersion of the mineral filler in the lipid phase 18 is carried out in the presence of a surfactant. 4. The feed or feed supplement according to product 3, wherein the surfactant has a cationic or zwitterionic polar head. 5. A feed or feed supplement according to product 3 or 4, wherein the surfactant is lecithin. 6. A feed or feed supplement according to any one of the preceding products, wherein the content of mineral filler in the lipid phase 18 is between 0.5 and 35% by weight, preferably less than 15%, based on the weight of the lipid phase 18. 7. A feed or feed supplement according to any one of the preceding products, comprising a gelling protein phase 11 located between a core 12 and a coating 14. 8. The feed or feed supplement of product 7, wherein the gelling protein phase comprises a mineral filler. A feed or feed supplement according to any one of the preceding products, wherein the core 12 and optionally the protein phase 11 are alternately coated with polymers of opposite charge, forming a coacervate. 9. A feed or feed supplement according to any one of the preceding products, wherein the coating 14 of the core 12 comprises n layers C of a biocompatible material having alternating stacks of positive and negative electrostatic charges that form crosslinked and structured coacervates in the stack of layers, n being at least equal to 2, the n layers C comprising at least one layer C+ comprising a biocompatible material having a positive electrostatic charge M+ and a crosslinker R− selected from a multivalent anion, and at least one layer C− comprising a biocompatible material having a negative electrostatic charge M− and a crosslinker R+ selected from a multivalent cation. 10. A feed or feed supplement as described in product 9, wherein the coating layer 14 advantageously comprises a layer of reinforcing material MR. 11. A feed or feed supplement according to any one of products 9 to 10, wherein the mineral filler or reinforcing material is selected from the group consisting of clays, silicas and electrostatically charged fibres, advantageously from the group of phyllosilicates. 12. The feed or feed supplement of product 11, wherein the phyllosilicate is a smectite. 13. A feed or feed supplement according to any one of the preceding products, wherein the aqueous phase A comprises a negatively charged carboxyl-functionalized polysaccharide, such as an alginate, in a content of 1-8 wt.%, preferably less than 5.5%, advantageously 1-4%, relative to the weight of the dry extract of the aqueous phase. 14. The feed or feed supplement of product 13, wherein aqueous phase A is gelled by reaction of a charged polysaccharide with a reactant such as a calcium salt in the presence of pyrophosphate or glucono-delta-lactone.
[0009] The presence of an exfoliated phyllosilicate type mineral filler, for example exfoliated smectite, in the lipid matrix 18 of the core has the advantage that it makes it possible to adjust the density of the products and therefore their floating capacity. This exfoliated mineral filler is in the form of separate sheets, to which it is possible to add up to 100 ml of water depending on the quality of the exfoliation.2 / g~800m 2 / g, advantageously 200m 2 / g~500m 2 Phyllosilicate sheets give it an extremely high surface area of 1000 nm / g. These sheets can adsorb small molecules such as oxygen. The exfoliated mineral fillers thus form a barrier against the penetration and diffusion of aggressive molecules from the outside, especially oxygen, towards the nutrients contained in the product. The fractal organization of the mineral fillers also allows them to microstructure the lipid phase 18 and to penetrate in three directions until they cover the entire lipid phase, thus contributing to the containment of nutrients and other molecules of interest. The presence of phyllosilicate sheets can also adsorb molecules of interest that bring further properties to the lipid phase 18. For example, phyllosilicate sheets with a high specific surface area can be a support for the dispersion of protective molecules such as polar antioxidants, even if they are insoluble or poorly soluble in the lipid phase. This is the case, for example, of vitamin C, certain water-soluble polyphenols, flavonoids, etc.
[0010] Furthermore, the gelation of the aqueous phase A dispersed in the lipid matrix 18 has the advantage of limiting the outward leakage of nutrients. It also makes it possible to stabilize the size of the particles by avoiding their coalescence, thus increasing the interfacial area between the aqueous phase A and the digestive agent, thus accelerating the release rate during the digestion phase. [Brief description of the drawings]
[0011] The invention is further illustrated in Figures 1 to 14, which are shown by way of example only: [Figure 1] 1 shows a first subject product of the invention diagrammatically in cross section, without taking into account respective dimensions; [Diagram 2] 2 shows a schematic cross-section of a second subject product of the invention; [Diagram 3] 1 shows a schematic cross-section of a third subject product of the invention. [Figure 4] 1 shows a schematic representation of one embodiment of the coating of the core of the subject product of the present invention. [Diagram 5] A scheme of the manufacturing method for the first product is shown. [Figure 6] 1 shows a scheme of an additional process for producing a third product. [Figure 7] 1 shows the size distribution of aqueous particles. [Figure 8] 1 shows the size distribution of lipid particles. [Figure 9] 1 shows the time course of iodine value measured during ageing of lipid particles in open air. [Figure 10] 1 shows images of lipid particles obtained by scanning electron microscopy. [Figure 11] 4 shows the curves according to the rheological behavior of the protein layer. [Figure 12] An example of protein particles obtained after gelation is shown. [Figure 13] 1 shows conductivity monitoring of the quantitative addition of charged biopolymers in water. [Figure 14] 1 shows the time course of the electrical conductivity of lipid particles as a function of the quantitative addition of charged biopolymers. [Figure 15] The basic diagram of small-angle scattering is shown. [Figure 16] 1 shows the small angle scattering spectrum of bentonite dispersed in sunflower oil. [Figure 17] Porod Iq 4 = SAXS data of the dispersion of bentonite in the f(q) representation. DETAILED DESCRIPTION OF THE PREFERRED EMBODIMENTS
[0012] The terms "object" or "characteristic" refer to the various components of a feed or feed supplement according to the invention.
[0013] The term "product" refers to the feed and feed supplement according to the invention obtained by stacking the various objects.
[0014] The term "gel" refers to a material that consists mainly of liquid but has behavior close to that of a solid due to an entangled three-dimensional network within the liquid. It is these entanglements that give gels their structure and their properties. The three-dimensional network of a solid diluted in a liquid can be the result of chemical or physical bonds, or of small crystals or other bonds that remain intact in the dispersion.
[0015] In the context of the present invention, the term "exfoliated mineral filler" means a mineral filler that has undergone exfoliation, i.e. a more or less complete separation of its individual sheets. The exfoliation process usually comprises three stages: - (1) pre-swelling of the phyllosilicate sheet by swelling in water; - (2) adsorption of hydrophobic molecules on the surface of the phyllosilicate particles to make them compatible with the dispersed lipid phase, e.g., lecithin; and - (3) Application of shear energy to separate phyllosilicate particles in solution.
[0016] In the context of the present invention, the specific surface area (Ss), also called "area per unit mass", represents the surface area (As) of an object per unit mass (M) and is generally expressed as m 2 It is expressed in units of a particle per gram. The specific surface area indicates the actual area of the surface available to an object, not the apparent surface.
[0017] FIG. 1 shows, diagrammatically and in cross section, a first product 10 comprising a lipid phase 18 containing a mineral filler according to one of the objects of the present invention, without taking into account the respective dimensions of each phase.
[0018] This first product 10 comprises a core 12, a protein phase 11, and a coating 14 of the assembly of the core 12 and the protein phase 11. The core 12 comprises an aqueous phase A in the form of spherical (or irregular) gel particles 16, which are dispersed in a lipid matrix 18. The protein phase 11 surrounds the core 12 and is surrounded by the coating 14.
[0019] A first feature or object of this first product 10 is that it comprises a gelled aqueous phase A which comprises water-soluble active substances, in particular nutrients. The gel particles 16 thus comprise water-soluble active substances, in particular nutrients.
[0020] Advantageously, the size of the gel particles 16 is between 1 and 200 μm, preferably between 20 and 100 μm.
[0021] The gelling of the aqueous phase A makes it possible to limit the leakage of nutrients and active substances from the particles 16. It also makes it possible to stabilise the particle size 16 by limiting coalescence and thus increasing the specific surface area of the aqueous phase A, i.e. the sum of the specific surface areas of each gelled particle 16, thus accelerating the release rate of the active substances contained in the digestive phase.
[0022] According to a preferred embodiment, the aqueous phase A comprises an anionic polysaccharide, such as an alginate, having a content of 1 to 4% by weight relative to the weight of the aqueous phase.
[0023] According to a preferred embodiment, the aqueous phase A comprises a carboxylic acid functionalized polysaccharide and is therefore negatively charged under suitable pH conditions, such as an alginate having a content of carboxylic acid functionalized polysaccharide of 1 to 8% by weight, advantageously 1 to 5.5% by weight, more advantageously 1 to 4% by weight, relative to the weight of the dry extract of the aqueous phase A, i.e. relative to the weight of the dry extract of the collection of gel particles 16.
[0024] The aqueous phase A may advantageously be a gel formed by reaction of a carboxyl-functionalized anionic polysaccharide with a calcium salt and an agent such as pyrophosphate or glucono-delta-lactone.
[0025] The calcium salt may be selected from the group consisting of calcium sulfate, calcium carbonate, calcium lactate, calcium citrate, calcium tartrate, calcium caseinate and calcium stearate, and mixtures thereof, in particular from the group consisting of calcium sulfate, calcium carbonate and calcium stearate, and mixtures thereof.
[0026] The solubility of the calcium salt is obtained by reaction with the protons (acids) released in situ, which can be generated by pyrophosphate or glucono-delta-lactone reagents in contact with water.
[0027] Advantageously, the aqueous phase A also contains an osmotic agent.
[0028] The osmotic agent may be selected from the group consisting of a sugar, a salt, a water-soluble polymer, preferably with a molecular weight of less than 150 kg / mol, and combinations thereof.
[0029] A preferred choice of osmotic agent could be sorbitol with a content of less than 5% by weight, relative to the weight of the aqueous solution, i.e. the weight of the aqueous phase A (in the complete formulation), so as not to make the final product indigestible. A content of sorbitol of 0.8% to 1.5% by weight is optimal. An advantageous use of Guérande salts is also possible, which also yield useful mineral salts.
[0030] Preferably, the content of aqueous phase A dispersed in the lipid matrix 18, and therefore the content of gel particles 16, is comprised between 10 and 50 volume %, preferably between 15 and 30 volume %, relative to the total volume of aqueous phase A and lipid matrix 18, i.e., relative to the total volume of the core 12.
[0031] Below 10% by volume, the volume of aqueous phase A is no longer sufficient to easily incorporate the water-soluble active substances and have good uniformity of composition of the core 12 of the product.
[0032] Above 50% by volume, it becomes extremely difficult to maintain a dispersed water emulsion, ie, the gel particles 16, in the lipid phase 18.
[0033] The aqueous phase A gel may include hydrophilic actives such as amino acids, vitamins, prebiotics, probiotics, antioxidants, and combinations thereof.
[0034] A second feature or object of this first product 10 is that the aqueous phase 16, or gel particles 16, are dispersed in a lipid matrix or phase 18.
[0035] Advantageously, the lipid matrix 18, which is the second object or characteristic of the product 10, comprises at least one vegetable or animal oil, in particular a fish oil, and at least one crystalline wax. The wax may be of animal (beeswax) or vegetable origin.
[0036] Preferably the waxes used are crystalline waxes having a melting temperature below 90 degrees Celsius, most preferably below 65 degrees Celsius.
[0037] The wax content is advantageously between 5 and 25% by weight, most advantageously between 10 and 20% by weight, relative to the total weight of the lipid matrix 18.
[0038] According to a preferred embodiment, the lipid matrix 18 is substantially spherical, and therefore the core 12 is substantially spherical and has a diameter of 10 to 1000 μm, preferably 200 to 400 μm.
[0039] The lipid matrix 18 may advantageously include vitamins.
[0040] Preferably, this lipid matrix 18 has a high content of omega-6 and omega-3, especially the DHA and EPA types.
[0041] The lipid matrix 18 advantageously comprises at least 1% by weight of omega-3 of the DHA and EPA type, based on the weight of the lipid matrix 18. It also preferably comprises less than 30% by weight of omega-3 of the DHA and EPA type, highly preferably less than 10% by weight, based on the weight of the lipid matrix 18.
[0042] According to an essential feature, the lipid phase 18 comprises an exfoliated mineral filler selected from the group consisting of clays, talc and phyllosilicates such as mica. The exfoliated mineral filler is advantageously in an amount of 100 ml.2 / g, advantageously 100m 2 / g~800m 2 / g, more preferably 200-500m 2 / g.
[0043] The phyllosilicate is preferably a smectite, which has the advantage that its layered structure with larger gaps between the layers than other phyllosilicates allows it to be swollen by small hydrophobic molecules, improving the exfoliation of the clay platelets and thus facilitating their dispersion in the lipid matrix 18. Mica and talc can also be exfoliated in this manner, but the energy required to disperse the thin sheets in the lipid matrix is much higher.
[0044] According to an advantageous embodiment, the content of mineral filler in the lipid matrix 18 is comprised between 0.5% and 35% by weight, preferably less than 15% by weight, ie between 0.5% and 15% by weight, relative to the weight of the lipid matrix 18.
[0045] The presence of this mineral filler in the lipid matrix 18 has several important advantages. Firstly, the filler allows to control the density so that the product can float when used in aquaculture. It also strengthens the resistance of the product to the action of oxygen by significantly reducing the diffusion rate in the core 12 of the product, acting as a barrier limiting the leakage of small molecules of nutrients and active substances. Finally, the extremely large surface area created by the smectite sheets allows the microstructuring of the lipid matrix 18 on the nanometer scale, which makes it possible to compartmentalize and influence the kinetics of the digestibility of the lipid matrix 18.
[0046] A third feature of this first product 10 is the gelled protein phase 11 which surrounds the lipid matrix 18 and thus the core 12. This protein phase 11 comprises a protein. This protein phase 11 is advantageously prepared from a protein dissolved in the aqueous phase A2 gel.
[0047] The term "protein" refers to amino acids and all oligomers and polymers thereof, particularly oligopeptides, polypeptides and proteins.
[0048] The presence of this protein phase 11 has the advantage of providing the target animal with amino acids necessary for its growth, in addition to the active substances, promoting the attractive properties of the feed 10.
[0049] Advantageously, the protein content of this protein phase 11 is between 6 and 95% by weight, relative to the weight of the dry extract of protein phase 11. This content is preferably between 45 and 80% by weight, relative to the weight of the dry extract of protein phase 11.
[0050] If the protein content is more than 95%, the protein blocks the reactive sites of the polysaccharides, making it difficult to gel the protein phase 11. If it is less than 6%, the nutritional contribution as a feed supplement is insufficient.
[0051] As shown in Figure 1, the protein phase 11 surrounds a single core 12 having a substantially spherical shape. However, depending on the process used to disperse the core 12 in the protein phase 11, a given product 10 may contain multiple cores 12 dispersed in the protein phase 11. As a result, the external shape of the product 10 and this protein phase 11 can vary greatly (see Figure 12).
[0052] The protein phase 11 preferably comprises negatively charged gellable polysaccharides such as alginates, pectins, xanthan, gellan gums, etc. These polysaccharides are advantageously present in the aqueous phase A2, in particular allowing their gelation by reaction of the polysaccharides with a gelling agent, which also advantageously allows cross-linking of the polysaccharides with one another.
[0053] Negatively charged polysaccharides can be functionalized with carboxylic acid, sulfonic acid, alcoholate or phosphate functional groups alone or in combination with positive charges (such as hyaluronic acid). Carboxylic acid functional groups are preferred. Physicochemical conditions are adjusted to have an excess of negative charges to promote gelation conditions.
[0054] Advantageously, the gelling protein phase 11 is crosslinked by the action of a gelling agent that is released with a delayed time, which may be, for example, a metal capable of forming a complex with the carboxyl functional groups of the target polysaccharide, i.e. a polysaccharide or an inorganic or organic oligomer of opposite charge to that of the polysaccharide present in the protein phase 11.
[0055] Adjustment of the crosslinking delay time from 15 minutes to several hours allows for accelerated mass mixing of the ingredients without mass gain of the gel, and therefore allows for shaping of the feed or feed supplement 10.
[0056] The gelling agent may include calcium, zinc, magnesium or transition metal cations and an acid proton source (such as pyrophosphate or glucono-delta-lactone) that is hydrolyzed in water to allow release of the ionic form.
[0057] The gelling protein phase 11 may comprise a gelling polysaccharide content of 0.5 to 4.5% by weight, preferably less than 2% by weight, relative to the weight of the gelling protein phase 11 during the preparation of said protein phase 11, i.e. before the final drying stage of the product 10.
[0058] The gelling protein phase 11 preferably comprises a content of gellable polysaccharides of between 2 and 20% by weight, preferably between 2 and 10% by weight, relative to the weight of the dry extract of the gelling protein phase 11 .
[0059] Below 2% by weight of alginate in the protein phase 11, insufficient gelling is observed for the stability of the product 10. Above 25% by weight, based on the weight of the dry extract of the protein phase 11, polysaccharides such as alginate act as laxatives by trapping more water and associated nutrients.
[0060] Advantageously, proteins in protein phase 11 include proteins less than 30 kDa in size, so digestion of these proteins can occur more quickly as there are fewer bonds to break in order to fragment the peptides into a size that can be absorbed in the intestine.
[0061] According to an advantageous embodiment, the protein phase 11 also contains dispersed mineral fillers such as silica, phyllosilicates, metal oxide type, etc. The mineral fillers are advantageously dispersed in the aqueous phase A2 gel.
[0062] This mineral filler, for example clay, has the advantage of being able to regulate the buoyancy of the product 10. It also forms a barrier against the diffusion of oxygen into the product 10. Indeed, the extremely large surface area caused by the smectite sheets allows a microstructuring of the protein matrix 11 on the nanometer scale, which makes it possible to compartmentalize and influence the dynamics of the digestibility of the protein matrix 11. The microstructure is obtained by the interaction of the positively charged sheets on the sides of the sheet with the negatively charged sheets at the maximum surface of the sheet containing the polysaccharide, such as alginate, or protein of the protein phase 11.
[0063] The mineral filler is preferably a phyllosilicate, very preferably a smectite.
[0064] The protein phase 11 advantageously comprises an osmotic agent.
[0065] The osmotic agent may be selected from the group consisting of a sugar, a salt, a water soluble polymer, preferably with a molecular weight of less than 150 kg / mol, and combinations thereof.
[0066] A preferred choice would be sorbitol, the content of which is less than 5% by weight relative to the weight of the aqueous solution, i.e. the weight of the aqueous phase A2 gel (in its complete formulation), in order not to make the final product 10 indigestible. A content of 0.8% to 1.5% by weight is optimal. An advantageous use of Guérande salts is also possible, which may result in useful mineral salts.
[0067] According to another advantageous feature, the protein phase 11 and the core 12 as a whole are of any shape with a maximum dimension between 500 μm and 5 mm.
[0068] The size of the product 10 according to the present invention can be easily adapted to the intended target to suit their eating capabilities.
[0069] Another subject of the invention is a feedstuff having a total protein content which may be between 20 and 70% by weight relative to the weight of the entire final product 10. This content is obtained after an optional final drying step of the product 10. The protein is substantially provided by the protein phase 11. In particular, 80 to 100% by weight, advantageously 90 to 100% by weight, of the protein of the feedstuff is provided by the protein phase 11.
[0070] Another subject of the invention is a feedstuff having a total protein content which may advantageously be between 40 and 80% by weight relative to the weight of the dry extract of the total final product 10. The protein is substantially provided by the protein phase 11. In particular, between 80 and 100% by weight, advantageously between 90 and 100% by weight, of the protein of the feedstuff is provided by the protein phase.
[0071] Another subject of the invention is a feed supplement having a total protein content which may be between 10 and 20% by weight relative to the weight of the entire final product 10. This content is obtained after an optional final drying step of the product 10. The protein is substantially provided by the protein phase 11. In particular, 80 to 100% by weight, advantageously 90 to 100% by weight, of the protein of the feed supplement is provided by the protein phase 11.
[0072] Another subject of the invention is a feed supplement having a total protein content which may advantageously be between 3 and 40% by weight relative to the weight of the dry extract of the total final product 10. The protein is substantially provided by the protein phase 11. In particular, 80 to 100% by weight, advantageously 90 to 100% by weight, of the protein of the feed supplement is provided by the protein phase 11.
[0073] Although the proteins of the protein phase 11 are at least partially predigested in the stomach of the animal, the gelation of this protein phase 11 in combination with the coating 14 constitutes a physical barrier to the release of these predigested proteins into the stomach. In fish, it is useful to limit the release of predigested proteins into the stomach, since their metabolism in the stomach generates digestive and kinetic energy, causing the excretion of ammonia type resulting from this catabolism, instead of being metabolized in the intestine of the animal, where their absorption is most efficient for the growth of these animals.
[0074] A fourth feature of this first product 10 is the inclusion of a coating 14 around the core 12 and protein phase 11 .
[0075] This coating 14 may comprise n layers C of biocompatible materials M+ and M−, in particular biopolymers, having alternating stacks of positive and negative electrostatic charges that form a structured coacervate by stacking the layers, where n is at least equal to 1.
[0076] This coating 14 may comprise n layers C of biocompatible materials M+ and M−, in particular biopolymers, having alternating stacks of positive and negative electrostatic charges that form cross-linked and structured coacervates by the stacking of layers, where n is at least equal to 2.
[0077] One or more layers C+ comprising a biocompatible material having a positive electrostatic charge M+ contain a crosslinker R− selected from polyvalent anions.
[0078] One or more layers C-, which comprise a biocompatible material having a negative electrostatic charge M-, contain a crosslinker R+ selected from multivalent cations.
[0079] Each layer C thus comprises a biocompatible material M having an electrostatic charge, i.e. a biocompatible material having functional ionizable and ionizable groups under suitable physicochemical conditions. These charges may be positive electrostatic charges, the biocompatible material denoted M+ comprising cationic functional groups, such as amine functional groups. These charges may be negative electrostatic charges, the biocompatible material denoted M- comprising anionic functional groups, such as carboxylic acid, sulfonic acid, alkoxide or phosphate functional groups.
[0080] Each layer C comprises, in addition to a biocompatible material M, a crosslinker R. This crosslinker also comprises electrostatic charges of opposite charge to those of material M. However, the total electrostatic charge of layer C corresponds to that of material M. Indeed, in layer C, the ratio (number of electrostatic charges of the biocompatible material, denoted nM / number of electrostatic charges of the crosslinker, denoted nR) (i.e. nM / nR) is strictly greater than 1, advantageously greater than 2 and more advantageously greater than or equal to 5.
[0081] Thus, the layer containing the material M+, denoted as layer C+, also contains a crosslinker containing negative charges, denoted as R-. Layer C is positively charged overall. Indeed, in layer C, the ratio (number of positive electrostatic charges of the biocompatible material, denoted as nM+ / number of negative electrostatic charges of the crosslinker nR-) (i.e. nM+ / nR-) is strictly greater than 1, advantageously greater than 2, and more advantageously greater than or equal to 5.
[0082] Thus, the layer containing the material M-, denoted as layer C-, also contains a crosslinker containing positive charges, denoted as R+. The layer C- is negatively charged overall. Indeed, in the layer C-, the ratio (number of negative electrostatic charges of the biocompatible material, denoted as nM- / number of positive electrostatic charges of the crosslinker nR+) (i.e. nM- / nR+) is strictly greater than 1, advantageously greater than 2, and more advantageously greater than or equal to 5.
[0083] In each type of layer C, adjusting the ratio nM / nR (either nM+ / nR- or nM- / nR+) makes it possible to adjust the hardness of the coating 14. By way of example, when the crosslinker is added at a content level making it possible to have a ratio nM / nR of 5 / 1, a very hard coating is obtained, and when the crosslinker is added at a content making it possible to have a ratio nM / nR of 100 / 1, a very soft mesh is obtained.
[0084] The ratio nM / nR advantageously varies from 2 / 1 to 300 / 1, more advantageously from 5 / 1 to 150 / 1.
[0085] This coating system 14 has the advantage of facilitating the adjustment of the thickness of the layer of the coating 14, and the wide selection of biocompatible materials, in particular biopolymers, M+ and M-, makes it possible to adjust the mesh of the biocompatible materials, in particular the biopolymers at the surface, and also hardening by the stronger or weaker crosslinking strength of this mesh. The adjustment of the hardness of the coating 14 makes it possible to adjust the release of the nutritional and / or physiologically active substances: the denser the hardening, the more reduced the meshing of the biopolymers and the slower the release. This type of crosslinked and structured coating 14 of multilayer C also makes it possible to obtain the structural stability necessary for the preservation of the feed 10, in particular its handling, until the consumption of the feed 10 and the release of the nutritional and / or physiologically active substances.
[0086] The crosslinking agent R+ is selected from polyvalent cations. Advantageously, the polyvalent cations are selected from the group consisting of alkaline earth metals, transition metals and poor metals.
[0087] Highly advantageously, the polyvalent cation is selected from the group consisting of cations of calcium, magnesium, manganese, iron, copper, zinc, aluminum, and combinations thereof.
[0088] It should be noted that the multivalent cations are provided by salts and therefore may also contain anions. What is important is that the compound used allows the release of cations that can react with the negative charges of the biocompatible material M- and thus contribute to the cross-linking of layer C-.
[0089] The crosslinker R- is selected from polyvalent anions. The term "polyvalent anion" means a compound that contains multiple negatively charged functional groups. The functional groups can be monovalent or polyvalent. According to a preferred embodiment, the polyvalent anion is a polyphosphate. The crosslinker R- is preferably selected from sodium trimetaphosphate (STMP), sodium hexametaphosphate and mixtures thereof, preferably sodium trimetaphosphate (STMP).
[0090] Advantageously, in each layer C, the biocompatible material M+ is a biopolymer, in particular chosen from positively charged polysaccharides, advantageously chosen from polypeptides, chitosan, derivatives of chitin, gums used as amine-functionalized texturing agents, such as functionalized guar gum, and mixtures thereof. More advantageously, the biocompatible material M+ is chosen from chitosan.
[0091] Advantageously, in each layer C+, the biopolymer M+ is chitosan and the crosslinker R- is advantageously sodium trimetaphosphate (STMP).
[0092] Advantageously, in each layer C-, the biocompatible material M- is a biopolymer, in particular chosen from negatively charged polysaccharides, advantageously chosen from polypeptides, pectins, gum arabic, xanthan gum, alginates, carrageenans, cellulose derivatives and mixtures thereof, and more advantageously chosen from alginates, pectins and mixtures thereof.
[0093] Advantageously, in each layer C-, the biopolymer M- is chosen from alginate or pectin and the crosslinker R+ is advantageously chosen from calcium cations.
[0094] Advantageously, in each layer C+, the crosslinking agent R- is introduced in a specific content making it possible to obtain a ratio nM+ / nR- of 5 / 1 to 150 / 1. In particular, in each layer C+, the crosslinking agent R- is introduced in a content of 0.5 g to 2 g per g of M+ for a high crosslinking rate and in a content of 15 to 70 mg per g of M+ for a low crosslinking rate.
[0095] Advantageously, in each layer C-, the crosslinking agent R+ is introduced in a specific content making it possible to obtain a ratio nM- / nR+ of 5 / 1 to 150 / 1. In particular, in each layer C-, the crosslinking agent R+ is introduced in a content of 0.5 g to 2 g for 1 g of M- for a high crosslinking rate and in a content of 15 to 70 mg for 1 g of M-.
[0096] Thus, advantageously, layer C comprises a bond between material M and cross-linking agent R, either by metal complexation for layer C- or by chemical cross-linking for layer C+. n is an integer. n is advantageously 15 or less, more advantageously 2 to 15, and preferably 2 to 10.
[0097] This variability in the number of layers C allows for easy implementation while allowing for a good compromise between encapsulation quality and sustained release in the intestine.
[0098] The outer layer of this coating 14 preferably consists of a positively charged polymer, layer C+, to have antibacterial properties and therefore improve the preservation of the feed or feed supplement.
[0099] The use of two cross-linking chemistries in the coating 14, metal complexing and chemical cross-linking chemistries, makes it possible to have a trigger for the release of nutrients as the digestive cycle progresses. Thus, protein digestion is promoted by the release in acidic medium of polyvalent metal ions (complexed with electron donors), which increases the permeability of the coating 14 by the acids present in the stomach, slowing the release of digesta, while the layer of polycations remains cross-linked by phosphoramide bridges obtained by the action of sodium trimetaphosphate (STMP). These final cross-linking points are then released by the action of the alkaline phosphatase enzyme, which is normally secreted by the liver and excreted by the bile into the intestine. Thus, the feed or feed supplement releases its pre-digested nutrients in the intestine at a slower rate, promoting the most favorable metabolic pathway for absorption efficiency and zoological performance of the target animal.
[0100] Advantageously, the core 12 and / or the protein phase 11 also comprise a charged polymer or a protein having a surface charge or a cationic, anionic or zwitterionic surfactant.
[0101] To generate these charges, it is also possible to specifically add charged biopolymers to the core 12 and / or to the protein phase 11. These are chosen from the anionic or cationic polymers mentioned above, but may combine charges, such as hyaluronic acid.
[0102] This makes it possible to adjust the residual or free charges by adjusting the pH conditions of the medium or by adjusting the stoichiometric balance of the complexation system of the protein phase 11.
[0103] The physicochemical system is adjusted to provide an excess of free amines originating from the proteins of the protein phase 11 which are positively charged at pH conditions below 9. This excess positive charge is a necessary condition for depositing the first layer of the anionic biopolymer C- of the coating 14.
[0104] In this case, the coating 14 starts with a first layer of cationic biopolymer C+, where the physicochemical system of the protein layer 11 instead has a significant excess of negative charges due to the balance of the components that compose it.
[0105] The coating 14 of the protein phase 11 and / or the core 12 may also comprise a layer of a reinforcing material MR.
[0106] These reinforcing materials MR may be selected from the group consisting of clay, silica, electrostatically charged fibers, and combinations thereof.
[0107] These reinforcing materials MR have a predominance of negative electrostatic charges on their surface and are therefore attracted by the positive surface charges of the coating 14, layer C+. The reinforcing layer may also be located between two layers of cationic biopolymer C+.
[0108] The reinforcing material MR is preferably a phyllosilicate, very preferably a smectite.
[0109] High specific surface area, i.e. 100m 2 The use of reinforcing materials with a specific surface area of more than 100 nm / g can promote interactions with the coacervate macromolecules strengthening their insertion in the coating 14 while developing large interactions, on the one hand resulting in a large interaction surface with the incoming molecules (oxygen, oxidant molecules) or the outgoing molecules (nutrients) and on the other hand increasing the mean free path manifested by a slower oxidation rate of nutrients and improved encapsulation of small molecules.
[0110] This coating 14 therefore consists of alternating positively and negatively charged layers of biopolymers C+ and C-, advantageously polysaccharides. In the animal's stomach, the pH is acidic and it is the mesh of the positively charged biopolymer, layer C+, that is most resistant to this acidic pH and ensures the integrity of the coating 14.
[0111] The layers C- of the coating are advantageously cross-linked by cations such as Ca++. These cross-links are soluble in acidic media and therefore, upon reaching a neutral to basic medium (the intestine), there is a real release of the assembly of layers of the coating 14. As soon as there is a breach in the coating 14, the enzymes of the bile penetrate into the core 12, causing the release of the lipids and their nutrients and active substances, and very rapidly releasing the aqueous phase particles 16 and their nutrients and active substances. This coating 14 therefore ensures a rapid release of all nutrients and active substances in the intestinal area of the monogastric animal, where their absorption during their passage is most effective.
[0112] The product 10 is designed to provide nutritional balance to rapidly growing animals that must cope with pathogens and the stresses of the breeding environment. The product 10 is therefore recommended in the form of feed or feed supplement for the early stages of monogastric species with high mortality, such as chicks in poultry farming or fingerlings in aquaculture. The flexibility of the formulation and the adjustment of properties also make it a useful product to add to the finishing of animals before sale.
[0113] FIG. 2 shows a second product 20 comprising a lipid phase 18 containing a mineral filler according to the subject matter of the present invention.
[0114] This second product 20 is similar to the first product 10, but has a simplified structure: it does not contain a protein phase between the core 12 and the coating 14. Like product 10, it contains a core 12 containing an aqueous phase consisting of aqueous particles 16 dispersed in a lipid matrix 18 and a coating 14.
[0115] This second product is particularly useful for providing specific nutrients or actives.
[0116] Figure 3 shows a third product 30 similar to the first product 10 of Figure 1. The third product 30 also comprises a lipid phase 18 which contains a mineral filler according to one of the objects of the present invention.
[0117] This third product 30 , compared to the first product 10 , also includes a covering or coating 34 of the lipid matrix 18 deposited between the lipid matrix 18 and the protein phase 11 .
[0118] Similar to coating 14 of product 10, this covering 34 comprises n layers C' of biocompatible material M, with alternating stacks of positive and negative charges forming a structured coacervate by layer stacking, n being at least equal to 1. Preferably, the number of layers n is between 2 and 10, n being an integer. Layers C' correspond to the same definition as layer C above. Biocompatible material M is as previously described for coating 14.
[0119] More specifically, this coating 34 comprises n layers C' of biocompatible material with alternating stacks of positive and negative charges forming a structured and cross-linked coacervate by layer stacking, n being at least equal to 2. This coating 34 thus comprises at least one layer C'+ corresponding to the same definition as layer C+ described above for coating 14, and at least one layer C'- corresponding to the same definition as layer C- described above for coating 14. Preferably, the number of layers n is between 2 and 10, n being an integer. The biocompatible material M is as described above for coating 14, i.e. as described above for M+ and M-.
[0120] The addition of this coating 34 makes it possible, if desired, to slow down the release of the active ingredient of the internal phase of the core 12. The outer layer of this coating 34 preferably consists of a positively charged polymer, layer C+, to have antibacterial properties and therefore improve the preservation of the feed or feed supplement.
[0121] This third structure may accommodate the requirement of a more delayed release of the core in the gastrointestinal tract, for example the release of prebiotics or probiotics which must remain intact until the final stages of the gastrointestinal tract.
[0122] FIG. 5 illustrates the various steps of a method for manufacturing the first product 10.
[0123] One or more cores 12 of the first product 10 are produced from a double water-in-oil-in-water emulsion, followed by filtration or decanting. This core 12 is then completed by a protein phase 11 which is shaped to the target size and shape, after which a coating 14 of engagement A is produced. The last optional step for producing the product is drying to bring the moisture content of the product 10 to a value below 10% by weight relative to the total weight of the product 10. This drying is carried out at low temperature, preferably below 50°C, for example between 18°C and 40°C.
[0124] Step (a) consists of preparing the aqueous phase by dispersing the required water-soluble active substance in water and adding gelling reagents, which are as described above for the aqueous phase A gels and may be polysaccharides, calcium salts, in particular calcium sulfate or calcium carbonate, in the presence of pyrophosphate or glucono-delta-lactone.
[0125] Step (a') consists of producing a gelling protein phase gel 11 by dispersing a protein containing a gelling agent, optionally an osmotic agent and optionally a mineral filler such as a phyllosilicate, in water.
[0126] In step (b), the aqueous phase resulting from step (a) is injected into a vegetable or animal oil to obtain a primary emulsion of aqueous particles in oil.
[0127] Thereafter, in step (c), the primary emulsion is allowed to stand or is moderately heated to less than 100°C, ideally less than 60°C, for example, 40°C to 60°C, to complete the gelling reaction of the aqueous particles and obtain robust gelled aqueous particles dispersed in oil (step (c)).
[0128] The first emulsion resulting from step (c) is then added to a mixture of at least one animal or vegetable oil and at least one liquid wax previously prepared. The mixture of oil and wax advantageously comprises between 1 and 50% by weight, more advantageously between 5 and 15% by weight of wax relative to the total weight of the mixture. As the crystalline wax used is liquid, the temperature of the mixture is higher than the melting temperature of the wax (step (d)).
[0129] In step (e), the entire first emulsion and the entire mixture of at least one oil and at least one liquid wax resulting from step (c) are introduced under stirring into an aqueous solution to obtain a second emulsion: this second emulsion comprises gelled aqueous particles of the first emulsion dispersed in a lipid matrix which is itself in the form of particles dispersed in an aqueous solution.
[0130] In step (f), this secondary emulsion from step (e) is cooled to a temperature below the solidification temperature of the crystalline wax present to stabilise the lipid particles.
[0131] In step (g), it remains to isolate the product cores or lipid particles by filtration or decanting and remove the aqueous phase.
[0132] After step (g), the lipid particles from step (g) are dispersed in the gelling protein phase 11 produced in step (a'). Homogenization is performed with minimal shear, which can be obtained, for example, by manual stirring (step (h)). The dispersion is then introduced, for example, into a cold extruder to shape the product through a die. At the exit of the die, the extrudate is continuously cut to the target dimensions by rotating blades to obtain an assembly consisting of cores 12 coated with protein phase 11 ready for coating.
[0133] This addition of protein phase 11 can also be carried out in a fluidized bed or by spheronisation.
[0134] The selected method, extrusion, fluidized bed, spheronization, is carried out at low temperatures, for example below 50° C., in the range of 18° C. to 50° C. (step (h)).
[0135] NOTE: Adjust the gelation rate of the protein phase 11 to be able to perform all the operations of step (h). Gelation is only achieved at the end of step (h) after a resting time allowing solidification of the layers.
[0136] It should be noted that due to the method of production by the production of an emulsion, the aqueous phase 16 and the lipid particles 18 have a relatively spherical shape. In contrast, the mass of protein phase 11 surrounding the lipid phase 18 of the product 20 obtained by cutting the extrudate exiting the die can have any shape.
[0137] Finally, in step (i), a coating 14 is formed from the assembly consisting of a protein phase 11 surrounding a lipid phase 18 derived from step (h) by immersion in a water bath provided with alternating solutions of cationic M+ and anionic M- biocompatible materials.
[0138] After the coating of step (i), the product is advantageously dried by air current at low temperatures below 50° C., preferably between 18 and 40° C., to a moisture content of less than 10% by weight relative to the total weight of the product. This makes it possible to extend the shelf life of the product. This last step (j) is optional.
[0139] FIG. 4 shows this formation of an aggregate coating 14 composed of a protein phase 11 surrounding a lipid phase 18 resulting from step (g) by successive addition of positively M+ and negatively M- charged biopolymers, advantageously polysaccharides.
[0140] NOTE: The representation of protein phase 11 in Figure 4 has been modified relative to representations in other figures for clarity.
[0141] NOTE: The aggregates are shown here diagrammatically in the shape of particles, but can be of any shape.
[0142] On the left side of Figure 4 is an assembly consisting of a core 12 of a first product 10 surrounded by a protein phase 11. This protein layer 11 contains a free surface charge which may be positive or negative.
[0143] The assembly is coated by adding an aqueous solution of a negatively charged biopolymer 52 (M-), such as a polysaccharide.
[0144] Due to electrostatic interactions, the negatively charged biopolymer M- covers the surface of the aggregates and forms a negative layer of coacervate C-.
[0145] An aqueous solution of the positively charged biopolymer 54M+ is then added to the dispersion containing the positively charged particles, which spontaneously covers the pre-deposited layer C-.
[0146] This operation is repeated alternating aqueous solutions of positively charged M+ and negatively charged M- biopolymers until a coating 14 is obtained that contains the desired number n of layers C. Typically, n is between 2 and 10.
[0147] Advantageously, in step (e), the continuous aqueous solution in which the second emulsion (lipid and wax emulsion) is produced comprises at least one osmotic agent and at least one surfactant.
[0148] The osmotic agent may be selected from the group consisting of a sugar, a salt, a water soluble polymer, preferably with a molecular weight of less than 150 kg / mol, and combinations thereof.
[0149] A preferred choice would be sorbitol with a content of less than 5% by weight relative to the weight of the continuous aqueous solution, so that the final product is not indigestible. A content of sorbitol between 0.8% and 1.5% by weight is optimal. The advantageous use of Guérande salts is also possible, which may also result in useful mineral salts.
[0150] The presence of an osmotic agent has the advantage of setting up an osmotic barrier that prevents the passage of active substances present in the aqueous phase of the first emulsion, which also contains, among others, an osmotic agent of the same type or different from that of the outer continuous phase; this inner aqueous phase is itself dispersed in the lipid phase. The osmotic agent ensures the balance of osmotic pressure. This avoids the pumping effect of nutrients through the lipid wall.
[0151] The protein phase 11 also advantageously contains an osmotic agent of the same type as that of the outer continuous phase or different from those mentioned above, thereby enhancing the effectiveness of the osmotic barrier.
[0152] Highly advantageously, the surfactant is selected from the group consisting of phospholipids, polymers such as carboxymethylcellulose (CMC), hyaluronic acid, polylysine, proteins such as casein, or hydrolysates of vegetable or animal proteins, surfactants, and combinations thereof.
[0153] Figure 5 also shows an additional optional step (a'') in which a dispersion of a mineral phase such as a clay is produced in at least part of the mixture of at least one oil and at least one liquid wax, animal or vegetable oil, and the liquid wax used in step (d). As indicated above, these clays are preferably phyllosilicates, very preferably smectites.
[0154] To facilitate the exfoliation of the clay sheets in the lipid medium, the dispersion is carried out in the presence of a surfactant, preferably having a polar head with a cationic function.
[0155] Advantageously, lecithin, betaine, polylysine, and combinations thereof may be used.
[0156] FIG. 5 also shows a separate, additional, optional step (c') where, after obtaining a primary emulsion of aqueous particles in oil (step (b)), these aqueous particles are subjected to high shear, such as in a rotor / stator, to reduce their size before being homogenized and fully gelled. This shear is preferably performed for a period of 2000 to 20,000 min -1 It is.
[0157] The preparation of the second product 20 is similar to that of product 10; the coating is produced immediately after obtaining the lipid particles in step (g).
[0158] FIG. 6 shows additional steps for producing a third product.
[0159] After step (g) making it possible to obtain the lipid particles 18 by filtration or decanting, a coating 34 of these lipid particles 18 is formed by successive additions of biopolymer solutions, advantageously of positively charged M+ and negatively charged M- polysaccharides (step (g')). The last addition is preferably of a positively charged M+ biopolymer. The steps for forming this coating 34 are as previously described for step (i).
[0160] The coated lipid particles 18 thus obtained are then dispersed in the protein phase 11 following step (g') and the aggregates are shaped by cold extrusion. The addition of the particles to the protein phase 11 can also be carried out by deposition in a fluidized bed or by spheronization. Cylinders or other shapes (depending on the die used) of the protein phase 11 in which the lipid particles 18 are dispersed are obtained. These extrudates then have to be cut, for example with a rotating blade, in order to obtain aggregates of cores 32 coated with the coating 34 dispersed in the protein phase 11 of the third product (step (h)).
[0161] To obtain these third products 30, it remains to produce the coating 14. This coating 14 is produced as previously described.
[0162] A final optional step of drying may then be carried out as described above under air flow at low temperature, preferably below 50° C., for example between 18 and 40° C., until a moisture content of less than 10% by weight relative to the total weight of the product is reached.
[0163] Characterization of exfoliated mineral fillers (clays) Small angle X-ray scattering (SAXS) Small angle X-ray scattering (SAXS) is a technique for obtaining information about the structure of materials on a scale of about 1 to 100 nm. Scales of the order of micrometers can also be investigated by USAXS. Furthermore, this technique allows the study of condensed media. The technique consists of sending an X-ray beam onto a sample and measuring the spatial distribution of the scattering produced by the sample. The measured intensity is then a function of the structural organization of the material, more precisely the phase difference. It is proportional to the difference in electron density.
[0164] A beam of X-rays is irradiated onto the sample to be analyzed. Photons of the beam interact with the electron clouds of the sample's atoms and are scattered by the sample. A detector placed after the sample can measure the scattering intensity as a function of the scattering angle (see Figure 15).
[0165] The direction of the scattering angle θ is also called the scattering vector (q). The size of the observed scale is inversely proportional to the scattering vector. The observed scale is larger for smaller scattering vectors.
[0166] The scattering intensity can be described as a function of the object shape (shape factor P(q)) and the object correlation (structure factor S(q)) as follows: I(q) = α.φ.(Δρ) 2 .P(q).S(q) In the formula, α: constant (-); φ: volume fraction of the sample; Δρ: phase difference between the object and the solvent.
[0167] Device: The instrument used for the analysis is a Xeuss 2.0 operated at Laboratoire Leon Brillouin, CEA (Saclay, France). A microfocus CuK alpha source with a wavelength of 1.54 Å and a power of 8 keV is used. The 2D detector is a Pilatus 3 1M from Dectris (Switzerland).
[0168] The two configurations have a detector size of 2.494 m (0.3 × 0.3 mm 2 beam), then 0.539 m (0.8 × 0.8 mm 2 of the beam) to achieve a focal length of 0.003 Angstroms. -1 <q<1オングストローム -1 This allows the signal to be normalized to cm -1 Obtain intensity in units and be quantitative in the analysis you perform.
[0169] Sample preparation: Efficient exfoliation of bentonite in lipid media (sunflower oil is used for SAXS experiments) requires following a protocol that facilitates three key steps of the dispersion process of these clays. -(1) Pre-swelling of the phyllosilicate sheet -(2) Adsorption of hydrophobic molecules on the surface of phyllosilicate particles to make them compatible with the dispersed lipid phase. - (3) Application of shear energy to separate phyllosilicate particles in a continuous lipid phase.
[0170] Step (1) is accomplished by adding a sufficient amount of water to impregnate the sheet. The protocol followed recommends using at least 10% water relative to the amount of bentonite used, although this amount can be increased to improve the quality of the exfoliation, and samples prepared for characterization by SAXS are pre-swollen with 0.5 g water per 1 g bentonite.
[0171] Step (2) is obtained by using lecithin as an exfoliant, which is adsorbed on the surface by ionic interactions. For the SAXS characterization, 0.3 g of lecithin was used for 1 g of bentonite. To facilitate its incorporation, it was pre-dissolved in water in step 1.
[0172] Step (3) can be achieved by any effective shearing or dispersing means. SAXS samples were obtained by dispersing pre-impregnated bentonite (steps (1) and (2)) in sunflower oil. The minimum production volume was 200 ml and shear was applied at 4000 rpm for 5 min in batch mode at ambient temperature using a 30 mm stirrer with an air gap of 150 μm.
[0173] For experimental purposes, 20% and 8% by weight solutions of bentonite were prepared in sunflower oil.
[0174] Results and interpretation: Bentonite solutions of 20 wt % and 8 wt % were measured by SAXS, and the spectra shown in FIG. 16 were obtained.
[0175] The measured spectra show the organization of bentonite on several scales. The signals are proportional to the amount of dispersed bentonite and have the same appearance. A shoulder is observed at high q, which can be interpreted as a characteristic distance of the material (structure peak) corresponding to a characteristic distance of 63 Å (2×π / q) for the first shoulder and 28 Å for the second shoulder. This can be characteristic of the intersheet distance of swollen or unswollen bentonite clusters. The shoulder can be interpreted as the amount of water provided in the sample preparation was not able to swell all the bentonite, leaving some swollen bentonite particles that are not completely exfoliated in the sample.
[0176] The rise of the small scattering vector (q → 0) is a characteristic signal of a fractal structure, q -4, which allows us to estimate the initial size of the macroscopic object, the dimension of which can be estimated to be about 50 nm (I(q)α exp(-q 2 Rg 2 / 3) the onset of the Guinier signal).
[0177] 0.008 <q<0.08では、q -3 The slope of q confirms the fractal structuring of bentonite, and indicates that compact clusters (usually q -4 Both the morphology of the elongated structures or connecting pathways between clusters (permeation pathways) and the morphology of the clusters are organized, giving a signal of q -2 The combination of these two signals gives q -3 This justifies the fractal dimension of the fractal assemblage, which is called a fractal aggregate.
[0178] Furthermore, the SAXS data of the bentonite dispersion expressed in Porod, Iq 4 = f(q) also allows a more qualitative approach by determining the specific surface area since it facilitates the reading of large scattering vector signals (large q) signals (see Figure 17).
[0179] This representation is commonly used to test two-phase media and evaluate their interfacial properties. In the model case of fractal aggregates, the Porod plateau characterizes the scattering surface area of the aggregates. In this case, this representation allows us to evaluate the net scattering surface area of the bentonite aggregates since they are organized in a lipid phase. We focus on the 20 wt% bentonite signal, since the signal is perfectly parallel to the 8 wt% bentonite (see Figure 17).
[0180] This shows two characteristic regimes of the Porod representation spectrum, with increasing intensity change as the scattering vector increases, followed by a 0.3 Å regime. -1 A plateau forms near Iq 4The scattering vector, which is constant, is now perturbed by the oscillations caused by the presence of the structural peak at 28 Å described in the previous spectrum. Thus, when q is 0.3 Å, -1 When the trend is toward -3 cm -1 It can project the Porod signal at .
[0181] q=0.25 angstroms -1 The emergence of the Porod plateau from makes it possible to calculate the specific surface area tested at the scale of dispersed bentonite clusters and at the scale of bentonite particles, which is sensitive to the quality of exfoliation.
[0182] Thus, it can be written as: When q→∞, Lim(I(q)×q 4 )=(2π×(Δρ) 2 ) x (surface / volume) In the formula, surface is the specific surface area.
[0183] The phase Δρ of bentonite and sunflower oil is 0.335×E -5 Angstrom -2 It was calculated that:
[0184] The volume fraction of a 20 wt% bentonite solution (bentonite density = 2.2, sunflower density = 0.94) was converted to 9.65 vol%.
[0185] This resulted in a specific surface area of the exfoliated bentonite of 285 m in liquid medium. 2 / g can be determined.
[0186] The specific surface area of raw bentonite is approximately 10 to 70 m 2 / g, always 100m 2 / g, these results show the importance of exfoliation for the quality of the interaction between the bentonite sheets and, in particular, the oxygen molecules that can be transferred to the product. In particular, the aforementioned results show that the exfoliation method in a lipid matrix leads to good exfoliation and that until penetration, an interconnected three-dimensional organization of the clay particles is observed.
[0187] This exfoliation process can be applied to other clays, especially all phyllosilicates.
[0188] Feed supplement manufacturing The following describes an example of the production of the first product, a feed supplement.
[0189] Preparation of the inner gelling aqueous phase The fabrication involves the following steps:
[0190] The beaker is filled with water. The hydrophilic supplement nutrients to be encapsulated are then added. These supplement nutrients represent approximately 30% by weight relative to the weight of the water placed in the beaker. The solution is then mixed in a Silverson L5M-A high shear rotor-stator type mixer at 1000 rpm (revolutions per minute) for 1 minute. 3.5% by weight of sodium alginate is then added to the solution. Mixing is performed in a high shear mixer at 2000 rpm for 5 minutes. After the alginate is completely dispersed, 0.5% by weight of pyrophosphate and 1.75% by weight of calcium sulfate are added simultaneously. The mixture is rapidly homogenized in a rotor-stator mixer at 2000 rpm, and then the entire aqueous phase is poured into a large amount of cod liver oil, which acts as a dispersion medium. The ratio of the volume of the oil to the volume of the aqueous phase is less than 3.4. The aggregate is mixed intensively in a high shear mixer at 2000 rpm in order to reduce the size of the water droplets in the oil before gelling of the aqueous phase. Allow to stand for 15 minutes to allow the aqueous phase particles to solidify.
[0191] The size distribution of the gelled aqueous particles obtained is shown in Figure 7. The average size of the aqueous phase particles obtained at a shear rate of 2000 rpm is 161 μm. The average size can be reduced by increasing the shear rate of the solution or by changing the viscosity of the alginate solution. A decrease in viscosity of more than 10 times was obtained by decreasing the concentration of alginate in the solution from 3.5 to 2 wt. %. In that case, the shear becomes more efficient and the average size of the particles decreases.
[0192] Preparation of crystalline lipid phases Preparation of the first beaker of molten wax A given mass of beeswax or sodium stearate and a mass of sunflower oil that is 15% more than the mass of beeswax or sodium stearate are added to the first beaker. The sum of the two components corresponds to 25.5% by weight of the total mass of the lipid phase produced. The first beaker is then placed in a water bath preheated to 75 ° C until the wax is completely melted (melting temperature of the wax at 60-63 ° C).
[0193] Preparation of exfoliated clay in oil in a second beaker In a second beaker, 100 weight units of rapeseed oil, 30 weight units of linseed oil, 1.24 weight units of betaine citrate, 1.24 weight units of soy lecithin, and 50 weight units of montmorillonite pre-impregnated with 10% by weight of water relative to the weight of montmorillonite (this exfoliation procedure carried out with 10% water is optimized for SAXS characterization with 50% water). The aggregate is mixed in a high shear mixer at 2000 rpm for 30 minutes. The mixture is completed with certain supplements such as vitamins A, E, D, K, less than 0.2 weight units. The production of exfoliated clay represents approximately 30% by weight relative to the total mass of the lipid phase produced. The quality of exfoliation of montmorillonite in oil can be evaluated by optical microscopy by observing the uniformity of the dispersion and the reduction of fine aggregates of several hundred μm.
[0194] Combine the prepared lipid phase in a third beaker In a third beaker held in a 70° C. water bath, combine the prepared oil phases according to the following ratios: - 44% by weight of the dispersion of gelling aqueous particles in the cod liver oil lipid matrix previously prepared; - 31% by weight of a mixture in a second beaker (rapeseed oil, linseed oil, exfoliated montmorillonite, etc.); and - 25% by weight of the mixture of the liquid wax previously prepared and sunflower oil.
[0195] This is homogenized in a high shear mixer at 1000 rpm for 2 minutes, resulting in an oil phase that is ready to be dispersed to form concentrated lipid particles.
[0196] Preparation of the outer aqueous phase An aqueous solution is prepared in a jacketed reactor equipped with stirrer and temperature control according to the following composition: a volume of water equivalent to 2.5 times the volume of the lipid phase to be dispersed; - 1% by weight, relative to the mass of the aqueous solution, of an osmotic agent (sorbitol or sodium chloride); and - 0.4% by weight of casein (a surfactant, which can be replaced by animal or vegetable proteins) relative to the mass of the aqueous solution.
[0197] This is homogenized until complete solubilization of the ingredients is achieved and the solution is heated to 65°C.
[0198] Lipid particle production The continuous aqueous phase is stirred at 450 rpm, while maintaining the temperature at 65°C, using a stirrer capable of dispersing solids.Then, the entire previously prepared lipid phase, which is held at 70°C, is rapidly poured into the outer aqueous phase.The dispersion is kept constant until it reaches about 62°C, stirring is reduced to 400 rpm, and cooled by reactor jacket until it reaches 60°C, stirring is reduced to 350 rpm, and cooling is accelerated by adding ice water to rapidly reach 45°C, and the lipid particles are allowed to cool to ambient temperature by reactor jacket, while maintaining stirring at 150 rpm.When the dispersion is below 25°C, the solidified lipid particles are filtered through a sieve.
[0199] The lipid particles thus obtained are characterized by size using a Malvern Mastersizer 3000 particle size analyzer in liquid dispersions produced by Hydro EV, using the sizer software (Fraunhofer equation). Measurements were carried out in three production tests: the same average size of the lipid particles of 330 μm was obtained in all three tests (Figure 8).
[0200] Figure 9 shows the evolution over time of the iodine value measured according to standard NF EN ISO 3961 (September 2013) during the aging of lipid particles in open air. Line L1 shows the reference iodine value obtained from the formulation of the particles. Lines L2 and L3 show the upper and lower 95% limits and line L4 is the evolution over time of the measured iodine value of the lipid particles. This line L4 shows that all measurements after the first measurement are between the upper and lower confidence limits, which allows to confirm the storage stability of the particles, especially due to the increased average path of the oxygen molecules imposed by the presence of clay. Thus, during storage, large variations are observed in the number of unsaturations (double bonds originating from omegas 3-6 and 9) provided by the oil used in the formulation.
[0201] FIG. 10 shows images of lipid particles obtained by scanning electron microscopy.
[0202] Outer protein layer - Production of protein layer by coating lipid particles Preparation of protein matrix containing lipid particles: Introduced into kneading type planetary mixer - 100 parts by weight of a protein preparation corresponding to the nutritional requirements of the target species; - 33 parts by weight of sodium alginate; - 8.3 parts by weight of pyrophosphate; - 33 parts by weight of calcium sulfate; - 1 part by weight of sorbitol (osmotic agent) - Nutritional additives according to nutritional targets (in amounts less than 2 parts by weight).
[0203] After homogenizing the solid, a certain amount of water equivalent to 600 parts by weight is added, followed by vigorously homogenizing for 10 minutes using a kneading type planetary mixer.
[0204] A mass of lipid particles equivalent to 630 parts by weight is introduced. Note: It must be taken into account that the residual moisture content of the lipid particles can vary from 2 to 50% by weight. Homogenization is then continued, with limited shear, until a homogenous paste is obtained. This paste is then introduced into a single-screw cold extruder to shape the paste through a die with a target diameter of the size of the feed supplement. The extrudate is continuously cut by a rotating blade to the target size of the feed supplement.
[0205] The protein particles are allowed to stand for 2 hours to solidify.
[0206] The solidification rate of the feed was measured using a TA-instrument ARES-G2 rheometer at 40 mm 2 The characteristics were evaluated using a moving cone and plate of 100 mm. A rotational shear force of 5° was applied at a frequency of 1 Hz, and the change in force over time was measured.
[0207] Figure 11 shows curves monitoring the rheological behavior of the protein layer for a protein phase obtained with 2% by weight of alginate and 15% by weight of protein relative to the total weight of the protein phase, which shows the evolution of the measured elastic moduli G' and G'' over time.
[0208] At short observation times, the destruction of the polyelectrolyte / protein gel is observed, the shear force G' decreases and several levels are marked. Then, beyond 3800 seconds, there is a recovery of the force, which indicates the appearance of a cross-linked region penetrating between the two shear plates. This cross-linking seems to saturate at 8300 seconds, after which there is a regression, probably related to the detachment of the solidified sample from the walls of the cone / plate.
[0209] From this it is estimated that mixing can be carried out for about 1 hour without the risk of destroying the gelling mechanism, with a continuous rest of 2 hours to achieve the maximum level of stiffness of the feed supplement. The protein particles thus obtained can be stored refrigerated (4°C) or used for a coating process by depositing biopolymers layer by layer.
[0210] Figure 12 shows an example of protein particles obtained after gelation, with sizes in the millimeter range.
[0211] Fabrication of coatings for controlled release by layer-by-layer deposition of biopolymers Coating layer by layer The procedure describes 100 g of lipid particles dispersed in 300 g of water supplemented with 1% sorbitol.
[0212] A stirrer is used (double blade stirrer) to promote good homogenization without inducing excessive shear of the solution.
[0213] The production is as follows: - 2000 ml of a first aqueous solution of chitosan (M+) at 0.1% by weight relative to the weight of the aqueous solution (containing 0.05% by weight of acetic acid); - 2000 ml of a second aqueous solution of 0.1% by weight sodium alginate (M-); - 200 ml of a third aqueous solution of calcium chloride (R+) at 2% by weight; and - 200 ml of a fourth aqueous solution of 0.5% by weight STMP(R-). Note: TSTP is obtained by chemical crosslinking of the introduced reactant STMP.
[0214] First, add 0.1% by weight sodium alginate solution; stir for 1-2 minutes between each addition. Then add the chitosan solution.
[0215] The procedure followed and the proportions of each addition were as follows (all % are by weight): - 20 ml of 0.1% sodium alginate solution; - 20 ml of 0.1% chitosan solution; - 60 ml of 0.1% sodium alginate solution; - 20ml of 0.5% STMP solution; - 10 ml of 0.1% chitosan solution; - 10 ml of 2% calcium chloride solution; - Montmorillonite 4.25 g; - 100 ml of 0.1% chitosan solution; - 80 ml of 0.1% sodium alginate solution; - 20 ml of 0.1% chitosan solution; and - 20 ml of 2% calcium chloride solution.
[0216] Stir at 370 rpm for 15 minutes. This procedure allows obtaining a coating with 7 layers, the first of which is an anionic sodium alginate layer and the last one is cationic chitosan. In the middle of the coating there is a layer of smectite (montmorillonite) sheets (MR). These operations can be repeated up to 7 times in the laboratory.
[0217] Feature evaluation: The lipid particles remain dispersed in the solution. Non-aggregation during addition of the charged biopolymer is confirmed by the naked eye.
[0218] A conductivity monitor of the solution conductivity monitors the deposition of charged biopolymers.
[0219] For reference, we measure the change in conductivity over time for a solution of pure water to which a 0.1% chitosan solution has been quantitatively added (curve C1), a solution to which 0.1% sodium alginate has been independently quantitatively added (curve C2), and finally a combination of the two (curve C3). The results obtained are shown in Figure 13.
[0220] Thus, the increase in solution conductivity is characterized during the addition of chitosan and sodium alginate, with the alginate exhibiting a higher conductivity. The combination of the two reagents results in a smaller sawtooth rise in conductivity compared to the anionic or cationic polymer alone, as the charges largely neutralize each other and the radius of gyration of the coacervate increases (resulting in a lower apparent conductivity).
[0221] Figure 14 shows the time course of the conductivity of a solution of lipid particles during the quantitative addition of charged biopolymers. This figure 14 shows that the addition of anionic (M-) and cationic (M+) biopolymers does not induce an increase in the conductivity of the solution, but rather decreases it. This is characteristic of the condensation of anionic and cationic biopolymers at the surface of the particles, since the large lipid particles contribute very little to the conductivity and the salts in the solution (osmotic agents) are trapped at the interface during condensation and no longer contribute to the conductivity of the solution, leading to a decrease in the overall conductivity of the solution.
[0222] Thus, the feeds and feed supplements that constitute a particular subject of the present invention are products with a modular structure capable of encapsulating various nutrients and active substances and releasing them in the digestive system of the target animal.
[0223] Stabilization by the coating material allows resistance to the acidic medium of the stomach while at the same time allowing rapid disintegration in the subsequent basic medium, ensuring extremely rapid and efficient release of the collection of nutrients and active substances wherever it is most effective.
[0224] The modular structure of the core allows the incorporation of 20 water-soluble active substances into the internal aqueous phase; in the first product, this incorporation is carried out in particles with a diameter of approximately 20-100 μm; it is also possible to incorporate approximately 20 lipophilic active substances into a matrix with a diameter of approximately 400 μm or less.
[0225] The manufacturing process itself ensures that these nutrients and active substances are highly preserved.
[0226] The products that are the subject of the present invention, due to their modular structure, have a very flexible use and, by varying the production conditions, it is possible to vary the respective dimensions of the particles and cores, as well as the nature and amount of the active substances and nutrients, in order to ultimately adapt them to all target animals.
Claims
1. A feed or feed supplement allowing controlled release of nutritionally and / or physiologically active substances for monogastric animals comprising a core 12 and a coating 14 on the core 12, characterized in that the core 12 comprises an aqueous phase A containing a water-soluble active substance and a lipid 18 containing a fat-soluble active ingredient, the aqueous phase A consisting of gel particles 16 dispersed in the lipid phase 18, and the lipid phase 18 comprising an exfoliated mineral filler selected from the group of phyllosilicates.
2. 2. A feed or feed supplement according to claim 1, wherein the phyllosilicate is a smectite.
3. A feed or feed supplement according to any one of claims 1 to 2, wherein the dispersion of the mineral filler in the lipid phase 18 is carried out in the presence of a surfactant.
4. 4. A feed or feed supplement according to claim 3, wherein the surfactant has a cationic or zwitterionic polar head.
5. 5. A feed or feed supplement according to claim 3 or 4, wherein the surfactant is lecithin.
6. 6. A feed or feed supplement according to any one of the preceding claims, wherein the content of mineral filler in the lipid phase 18 is between 0.5 and 35% by weight, preferably between 0.5% and 15% by weight, relative to the weight of the lipid phase 18.
7. A feed or feed supplement according to any one of claims 1 to 6, comprising a gelling protein phase (11) located between the core (12) and the coating (14).
8. 8. A feed or feed supplement according to claim 7, wherein the gelling protein phase 11 comprises a mineral filler.
9. 9. A feed or feed supplement according to any one of claims 1 to 8, wherein the coating 14 of the core 12 comprises n layers C of a biocompatible material with alternating stacking of positive and negative electrostatic charges which form crosslinked and structured coacervates in the stack of layers, n being at least equal to 2, the n layers C comprising at least one layer C+ comprising a biocompatible material with a positive electrostatic charge M+ and a crosslinker R− selected from a multivalent anion, and at least one layer C− comprising a biocompatible material with a negative electrostatic charge M− and a crosslinker R+ selected from a multivalent cation.
10. 10. A feed or feed supplement according to claim 9, wherein the coating (14) comprises at least one layer of reinforcing material MR.
11. A feed or feed supplement according to any one of claims 8 to 10, wherein the mineral filler or reinforcing material MR is selected from the group consisting of clays, silicas and electrostatically charged fibres, advantageously from the group of phyllosilicates.
12. 12. A feed or feed supplement according to claim 11, wherein the phyllosilicate is a smectite.
13. 13. A feed or feed supplement according to any one of the preceding claims, wherein the aqueous phase comprises a negatively charged carboxyl functionalised polysaccharide, such as an alginate, in a content of 1-8% by weight relative to the weight of the dry extract of the aqueous phase.
14. 14. A feed or feed supplement according to claim 13, wherein the aqueous phase A is gelled by reaction of a charged polysaccharide with a reactant such as a calcium salt in the presence of pyrophosphate or glucono-delta-lactone.
Citation Information
Patent Citations
Composite fishery nutritional microcapsule feed and breeding method
CN105994948A
Feed for aquatic and its production
JP1987011058A
Feed additive for ruminant
JP1995289172A
Microcapsule for feed
JP1998327770A
Fish oil-containing feed
JP2012183004A
